Navigation Links
Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City
Date:9/18/2009

SAN CARLOS, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2009 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Tuesday, September 22, 2009 at 10:30 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until October 25, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for partners, which include leading biopharmaceutical companies, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug dev
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Nektar Announces UCBs Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
2. Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
3. Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
5. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Announces Second Quarter 2008 Results
7. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
8. Nektar Therapeutics Announces First Quarter 2008 Results
9. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
10. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
11. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... forms of the protein cyclin E renders the ... (ER+) breast cancers, researchers from The University of ... Clinical Cancer Research . , The M. ... professor in M. D. Anderson,s Department of Experimental ... Stringer Professor in Medical Oncology, found evidence that ...
(Date:2/9/2010)... often in men with fewer complications, study finds , , ... that women are more likely than men to fail ... undergo the procedures five times as often as women ... in the February issue of HeartRhythm Journal , ... between 2005 and 2008. They underwent pulmonary vein antrum ...
(Date:2/9/2010)... reports improvement in thinking skills, , , TUESDAY, Feb. ... improve thinking, learning and memory skills in people ... research says. , Huntington,s affects movement, behavior and ... die within 10 to 30 years of its ... and increase as Huntington,s progresses, leading to the ...
(Date:2/9/2010)... 9 The National Association of ... in the fight against childhood obesity through better ... as she launches her own campaign against ... ,, "We are proud to support this new ... resources it brings is a very welcome addition ...
(Date:2/9/2010)... Initiative on Childhood Obesity ,, A t tr ... t er l ing K. Spe i ... C EO of t he W.K. Ke ... CREEK, Mich. , Feb. 9 The W.K. Kellogg Foundation ... to take action against childhood obesity. We,re excited about her personal passion for ...
Breaking Medicine News(10 mins):Health News:Low forms of cyclin E reduce breast cancer drug's effectiveness 2Health News:Low forms of cyclin E reduce breast cancer drug's effectiveness 3Health News:Drug May Ease Cognitive Effects of Huntington's 2Health News:NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity 2Health News:NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity 3Health News:Changing the Course of Kid's Health 2Health News:Changing the Course of Kid's Health 3Health News:Changing the Course of Kid's Health 4Health News:Changing the Course of Kid's Health 5
... 17 SynCare, LLC, today announced that,Ian Duncan has ... and expert in the field of disease management and ... and knowledge to the SynCare board,of directors. , ... Ian Duncan has joined our team," commented Stephanie,DeKemper, Vice ...
... continue progress. Broadcast video of President Sirleaf,s speech onboard the Africa Mercy, ... registration at www.mercyshipsnews.org or upon request. , ... Monrovia Liberia, ... the Free Port of Monrovia, Liberia, this past weekend, wrapping up four ...
... easier , ... Belleville, Ill. (Vocus) December 17, 2008 ... time to allow people to choose the plan that best meets ... and uncertain how to evaluate them, according to Allsup , ...
... Spangenberg, Shibley & Liber LLP were recently selected by their peers ... The recognition highlights the medical malpractice and personal injury expertise of ... ... 2008 -- Five Cleveland lawyers concentrating their practice on personal injury ...
... (TSX: RBM, OTCBB: RPBIF) today announced that Robert Pilz, ... the Company. Livleen Kaler, Director, Finance and Administration will ... , About Response Biomedical ... develops, manufactures and markets rapid on-site diagnostic tests for ...
... 16 A recent study from the, University of California, ... found,that strawberries may reduce the risk of heart disease. ... improve function of the,endothelium -- the cells that line the ... In the study, researchers found ...
Other Medicine News:Health News:SynCare Announces Ian Duncan Joins Board of Directors 2Health News:Mercy Ship Sails On From Liberia After Four-Year Rebuilding Effort 2Health News:Mercy Ship Sails On From Liberia After Four-Year Rebuilding Effort 3Health News:Allsup Outlines 10 Essential Questions People Need to Ask when Evaluating Medicare Plans 2Health News:Allsup Outlines 10 Essential Questions People Need to Ask when Evaluating Medicare Plans 3Health News:Allsup Outlines 10 Essential Questions People Need to Ask when Evaluating Medicare Plans 4Health News:Allsup Outlines 10 Essential Questions People Need to Ask when Evaluating Medicare Plans 5Health News:Allsup Outlines 10 Essential Questions People Need to Ask when Evaluating Medicare Plans 6Health News:Cleveland Injury Attorneys Among 'The Best Lawyers in America' 2Health News:Cleveland Injury Attorneys Among 'The Best Lawyers in America' 3Health News:Cleveland Injury Attorneys Among 'The Best Lawyers in America' 4Health News:Response Biomedical Corporation Announces Change of Executives 2Health News:Response Biomedical Corporation Announces Change of Executives 3Health News:Response Biomedical Corporation Announces Change of Executives 4Health News:Recent UC Davis Study Finds Strawberries May Reduce Risk of Heart Disease 2
(Date:2/8/2010)... ST. LOUIS , Feb. 8 ... Allied Healthcare Products (Nasdaq: AHPI ) narrowly back ... 2010. ,, Sales for the quarter ended December ... $12.5 million during the same quarter last ... quarter. However, Allied,s costs of sales were reduced even ...
(Date:2/8/2010)... FRANKLIN LAKES, N.J. , Feb. 8 /PRNewswire/ ... and Company), announced today the launch of BD Microtainer® ... new product is designed to improve the safety, accuracy ... in patients with veins that can be difficult to ... elderly. The new BD Microtainer MAP product is also ...
(Date:2/8/2010)... Transgenomic, Inc. (OTC Bulletin Board: TBIO) ... study with a leading pharmaceutical company that validates ... detect colorectal tumor-associated KRAS mutations that determine efficacy ... plasma samples in which the mutation levels were ... methodologies such as Sanger sequencing. ,, The study, ...
Breaking Medicine Technology:Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6BD Launches New Device Designed to Improve Safety, Accuracy and Turnaround Time of Blood Collection in Patients with Fragile Veins 2Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR 2Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR 3Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR 4The San Francisco SPCA Launches Online Guide for Summer Pet Health 26 Safety 53233 1The San Francisco SPCA Launches Online Guide for Summer Pet Health 26 Safety 53233 2The San Francisco SPCA Launches Online Guide for Summer Pet Health 26 Safety 53233 3Governor Eliminates Funding to Domestic Violence Programs 53230 1Governor Eliminates Funding to Domestic Violence Programs 53230 2Metabolife 28R 29 Reminds Us That the Little Things We Do Can Bring Positive Change to Our Lives and the Lives of Others 53228 1Metabolife 28R 29 Reminds Us That the Little Things We Do Can Bring Positive Change to Our Lives and the Lives of Others 53228 2
... DIEGO, March 9 Cardium Therapeutics (NYSE Alternext ... Inc., today reported that positive clinical findings demonstrating ... cooling techniques during robotic-assisted radical prostatectomy surgery will ... Urology and is now available online ...
... dosed every two weeks met the primary efficacy ... alfa-2a dosed weekly in patients with genotype 1 ... Albuferon had comparable rates of serious and/or severe ... global marketing applications planned in fall 2009 -ROCKVILLE, ...
Other Medicine Technology:Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 2Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 3Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 4Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 5Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 6Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 7Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: